SARS-CoV-2, the causative agent of COVID-19, has been responsible for over 42 million
infections and 1 million deaths since its emergence in December 2019. There are few …

SARS-CoV-2 has caused the global COVID-19 pandemic. Although passively delivered
neutralizing antibodies against SARS-CoV-2 show promise in clinical trials, their mechanism …

Summary SARS-CoV-2 neutralizing antibodies (NAbs) protect against COVID-19, making
them a focus of vaccine design. A safety concern regarding SARS-CoV-2 antibodies is …

Summary SARS-CoV-2-neutralizing antibodies (NAbs) protect against COVID-19. A concern
regarding SARS-CoV-2 antibodies is whether they mediate disease enhancement. Here, we …

Neutralizing antibodies are known to have a crucial role in protecting against SARS-CoV-2
infection and have been suggested to be a useful correlate of protection for vaccine clinical …

Multiple monoclonal antibodies have been shown to be effective for both prophylaxis and
therapy for SARS-CoV-2 infection. Here we aggregate data from randomized controlled …

Effective therapies are urgently needed for the SARS-CoV-2/COVID-19 pandemic. We
identified panels of fully human monoclonal antibodies (mAbs) from large phage-displayed …

The emergence of SARS-CoV-2 led to pandemic spread of coronavirus disease 2019
(COVID-19), manifesting with respiratory symptoms and multi-organ dysfunction. Detailed …

Understanding the properties and mechanisms by which antibodies provide protection is
essential to defining immunity. Although neutralizing antibodies have been proposed as a …

SARS-CoV-2 antibody therapeutics are being evaluated in clinical and preclinical stages. As
of 11 October 2020, 13 human monoclonal antibodies targeting the SARS-CoV-2 spike …